Diabetes - Ozempic Drug Quantity Management Policy - Per Days
Defines per-days quantity limits for Ozempic (semaglutide subcutaneous injection) across strengths and packaging for Cigna-administered health benefit plans, including retail and home delivery maximums and a statement that the product is covered as medically necessary when criteria are met. No overrides to per-days limits are permitted.
New policy created to add additional quantity limits to approve ONE claim collectively for ONE GLP-1 agonist or GLP-1/GIP agonist every 21 days at retail or home delivery.
The quantity limit of ONE claim of ONE GLP-1 agonist or GLP-1/GIP agonist to be dispensed every 21 days at retail or home delivery was removed from this policy.
Coverage Summary
Background: Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.